1,656 results on '"Lam, Raymond W."'
Search Results
2. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
3. Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report
4. Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder
5. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression
6. Assessing remission in major depressive disorder using a functional-structural data fusion pipeline: A CAN-BIND-1 study
7. Personalized relapse prediction in patients with major depressive disorder using digital biomarkers
8. A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study
9. Gray matter volume drives the brain age gap in schizophrenia: a SHAP study
10. Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
11. An empirical analysis of structural neuroimaging profiles in a staging model of depression
12. Relation of hippocampal volume and SGK1 gene expression to treatment remission in major depression is moderated by childhood maltreatment: A CAN-BIND-1 report
13. Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report
14. Predicting recurrence of major depressive episodes using the Depression Implicit Association Test: A Canadian biomarker integration network in depression (CAN-BIND) report
15. Response trajectories during escitalopram treatment of patients with major depressive disorder
16. The course of insomnia symptoms during the acute treatment of major depressive disorder: A CAN-BIND-1 report
17. Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study
18. Barriers and facilitators to technology-enhanced measurement based care for depression among Canadian clinicians and patients: Results of an online survey
19. Advancing equitable access to digital mental health in the Asia-Pacific region in the context of the COVID-19 pandemic and beyond: A modified Delphi consensus study
20. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
21. Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for depression (CAN-BIND) study
22. Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report
23. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report
24. Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress – an animal model of depression
25. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
26. Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report
27. Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report
28. A Randomized Evaluation of MoodFX, a Patient-Centred e-Health Tool to Support Outcome Measurement for Depression: Une évaluation randomisée de MoodFX, un outil de santé en ligne centré sur le patient pour soutenir la mesure du résultat dans la dépression.
29. Atypical brain aging and its association with working memory performance in major depressive disorder
30. Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report
31. Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials
32. Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series
33. White matter microstructure in youth at risk for serious mental illness: A comparative analysis
34. The Quality of Life in Bipolar Disorder (QoL.BD) questionnaire a decade on – A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder
35. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
36. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report
37. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
38. Comparison of the Efficacy Between Standard Measurement-Base Care (MBC) and Enhanced MBC for Major Depressive Disorder: A Pilot Study.
39. Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy.
40. Cognitive Dysfunction in the Workplace: Focus on Depression
41. Predictors of cognitive impairment in treatment-resistant depression
42. Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder
43. Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study
44. Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers
45. Functional neuroimaging biomarkers of anhedonia response to escitalopram plus adjunct aripiprazole treatment for major depressive disorder
46. Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review
47. Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
48. Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
49. Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report
50. Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: a situational analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.